News Headlines

  1. AtomVie Global Radiopharma Supplies The First Patient Dose Of 225Ac-SSO110 For Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial In Extensive-Stage Small Cell Lung Cancer And Merkel Cell Carcinoma 11/12/2025

    AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum Therapeutics' (Ariceum) 225Ac-SSO110, a potentially first- and best-in-class Actinium-225-labelled antagonist of the somatostatin type 2 receptor (SSTR2), being evaluated in Ariceum's Phase 1/2 clinical trial (SANTANA-225) for the treatment of extensive-stage small cell lung cancer (SCLC) and Merkel Cell Carcinoma (MCC).

  2. Strategic Partnership Between Sanyou Bio And Yugong Bio To Accelerate Expansion In High-End Synthetic Enzyme Market 11/11/2025

    Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes.

  3. Armata Pharmaceuticals Announces Formal Commissioning Of State-Of-The-Art cGMP Phage Manufacturing Facility In Los Angeles, California 11/10/2025

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its state-of-the-art current Good Manufacturing Practice ("cGMP") manufacturing facility in Los Angeles, California, has been formally commissioned.

  4. Novartis Opens New Radioligand Therapy Manufacturing Facility In California As Part Of $23B US Expansion Plan 11/10/2025

    Novartis, a leading global innovative medicines company, today announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California.

  5. Codexis Announces Signing Of Lease For GMP Manufacturing Facility 11/10/2025

    Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California.

  6. WuXi XDC And Standard Chartered China Sign MOU 11/7/2025

    WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced the signing of a Memorandum of Understanding (MOU) with Standard Chartered Bank (China) Limited (“Standard Chartered China”).

  7. LTS Completes Acquisition Of Renaissance Lakewood, Expanding Global CDMO Capabilities 11/7/2025

    LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company today announced the successful closing of its acquisition of Renaissance Lakewood, LLC (“Renaissance”), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms.

  8. BIOVECTRA And Revolution Biomanufacturing Partner To Deliver Integrated mRNA Design And GMP Production Services 11/6/2025

    BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

  9. Vector BioMed Expands LENTIVERSE™, Rebrands to Advance CGT 11/6/2025

    Vector BioMed expands LENTIVERSE™ with two solutions, VectorCraft and LaunchSuite, to accelerate global gene therapy access through transparent economics, streamlined manufacturing, and a bold new brand.

  10. Abzena And Mabqi Announce Strategic Partnership To Offer Integrated Discovery Through Development Solution 11/6/2025

    This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.